Search clinical trials for: IBI319

Total 361 results

Innovent Biologics (Suzhou) Co. Ltd.

Recruiting

IBI310 in Combination With Sintilimab in Patients With Advanced Biliary Tract Cancer

Advanced Biliary Tract Cancer

China
Innovent Biologics (Suzhou) Co. Ltd.

Completed

A Phase II Clinical Study to Assess the Efficacy and Safety of IBI310 or Placebo Combined With Sintilimab for Advanced Cervical Cancer Subjects Who Have Failed or Cannot Tolerate First-line or Above Platinum-based Chemotherapy

Advanced Cervical Cancer

China
Harbin Medical University
Innovent Biologics (Suzhou) Co. Ltd.

Not yet recruiting

Study of IBI343 in Subjects With Advanced Gastric/Gastroesophageal Junction Adenocarcinoma

Advanced Gastric/Gastroesophageal Junction Adenocarcinoma
Innovent Biologics (Suzhou) Co. Ltd.
Innovent Biologics (USA), Inc.

Withdrawn

A Platform Study of Novel Immunotherapy Products in Participants With Previously Treated Unresectable or Metastatic Cutaneous Melanoma

Metastatic Cutaneous Melanoma | Unresectable Cutaneous Melanoma

United States, Germany, France, Australia, Spain, Switzerland, United Kingdom
Innovent Biologics (Suzhou) Co. Ltd.

Terminated

The Study of IBI310 in Combination With IBI308 Compared to High-Dose Interferon In Patients With Acral Melanoma That Has Been Removed by Surgery

Acral Melanoma That Has Been Removed by Surgery

China
Innovent Biologics (Suzhou) Co. Ltd.

Active, not recruiting

Study of the Efficacy and Safety of IBI319 in Patients With Advanced Malignant Tumors

Advanced Malignant Tumors

China
Innovent Biologics (Suzhou) Co. Ltd.

Terminated

A Safety, Tolerability, and Efficacy Study of IBI314 in Patients With Mild to Moderate COVID-19

COVID-19

China
Innovent Biologics (Suzhou) Co. Ltd.

Recruiting

A Multicenter, Open-label Extension Study Evaluating the Efficacy and Safety of IBI311 in Subjects With Thyroid Eye Disease

Thyroid Eye Disease, TED

China
Innovent Biologics (Suzhou) Co. Ltd.

Completed

Study of IBI318 in Participants With Advanced Malignancies

Advanced Malignancy

China
Tongji Hospital
Wuhan University; Henan Cancer Hospital; Qilu Hospital of Shandong University; Hubei... and other collaborators

Recruiting

Sintilimab Plus Bevacizumab in Recurrent/Persistent Ovarian Clear Cell Carcinoma (INOVA)

Ovarian Clear Cell Carcinoma

China
Innovent Biologics (Suzhou) Co. Ltd.

Terminated

Study of IBI318 in Patients With Advanced Cutaneous Squamous Cell Carcinoma

Advanced Cutaneous Squamous Cell Carcinoma

China
Innovent Biologics (Suzhou) Co. Ltd.

Completed

IBI310 in Combination With Siltilimab in Subjects With Anti-PD-1/PD-L1 Resistance R/M NPC

NPC

China
Peking University
Innovent Biologics (Suzhou) Co. Ltd.

Unknown

Efficacy and Safety Evaluation of Sintilimab in Combination With IBI310 as Treatment in Patients With EBV-Positive Gastric Cancer

Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma

China
Innovent Biologics (Suzhou) Co. Ltd.

Completed

IBI310 (Anti-CTLA-4) in Combination With Sintilimab in Patients With Non-small-cell Lung Cancer (NSCLC)

NSCLC (Non-small-cell Lung Cancer)

China
Innovent Biologics (Suzhou) Co. Ltd.

Completed

A Study of IBI311 in Subjects With Active Thyroid Eye Disease

Thyroid Eye Disease

China
Innovent Biologics (Suzhou) Co. Ltd.

Completed

A Study of IBI311 in Healthy Volunteers

Healthy

China
Innovent Biologics (Suzhou) Co. Ltd.

Completed

Single Dose Tolerability and Pharmacokinetics of IBI112 in Healthy Subjects

Healthy Subjects

China
Innovent Biologics (Suzhou) Co. Ltd.

Recruiting

IBI334 in Subjects With Unresectable, Locally Advanced or Metastatic Solid Tumors

Solid Tumors

Australia
Innovent Biologics (Suzhou) Co. Ltd.

Unknown

A Study to Evaluate the Efficacy and Safety of Sintilimab in Combination With IBI305 (Anti-VEGF Monoclonal Antibody) Compared to Sorafenib as the First-Line Treatment for Advanced Hepatocellular Carcinoma.

Hepatocellular Carcinoma

China
Innovent Biologics (Suzhou) Co. Ltd.

Recruiting

A Study Evaluating the Safety, Tolerability, and Initial Efficacy of IBI110 in Subjects With Advanced Malignant Tumors

Advanced Malignancies

China
Innovent Biologics (Suzhou) Co. Ltd.

Active, not recruiting

A Study to Evaluate IBI112 in the Treatment of Psoriasis With Moderate to Severe Plaque Psoriasis

Psoriasis

China
Innovent Biologics (Suzhou) Co. Ltd.

Recruiting

IBI112 in Moderate to Severe Plaque Psoriasis With Randomized Withdrawal and Re-treatment

Psoriasis

China
Peking University

Recruiting

Sintilimab Combined With IBI310 and Surufatinib for the Treatment of G3-NET and NEC

Neuroendocrine Neoplasm

China
Innovent Biologics (Suzhou) Co. Ltd.

Completed

A Study to Evaluate IBI112 in the Treatment of Subjects With Moderate to Severe Plaque Psoriasis

Psoriasis

China
Innovent Biologics (Suzhou) Co. Ltd.

Completed

A Phase Ia/Ib Study of IBI315 in Patients With HER2-expressing Advanced Solid Tumor

Advanced Solid Tumor

China
Peking University People's Hospital

Active, not recruiting

A Study of IBI311 in Subjects With Steroid-resistant, Thyroid Associated Ophthalmopathy

Thyroid Associated Ophthalmopathy

China
Innovent Biologics (Suzhou) Co. Ltd.

Terminated

A Safety, Tolerability, and Efficacy Study of IBI314 in Ambulatory Patients With COVID-19

COVID-19

United States
Hunan Province Tumor Hospital
Xiangya Hospital of Central South University

Recruiting

The Efficacy and Safety of IBI363 in Solid Tumors. (Promise)

Advanced Solid Tumor

China
Hunan Province Tumor Hospital

Recruiting

The Efficacy and Safety of the Bispecific Anti-PD-1/PD-L1 Antibody IBI318 Combined With Lenvatinib in NSCLC.

Non-Small Cell Lung Cancer

China
Innovent Biologics (Suzhou) Co. Ltd.

Completed

Clinical Study of IBI362 in Healthy Chinese Male Subjects

Overweight/Obesity

China
Innovent Biologics (Suzhou) Co. Ltd.

Completed

A Phase I Study of IBI325 in Patients With Advanced Solid Tumor

Solid Tumor

China
Innovent Biologics (Suzhou) Co. Ltd.

Completed

A Study Evaluating the Safety, Tolerability, and Initial Efficacy of Recombinant Human Anti-T-cell Immunoreceptor With Ig and ITIM Domains (TIGIT) Monoclonal Antibody Injection (IBI939) in Subjects With Advanced Malignant Tumors

Advanced Malignancies

China
Innovent Biologics (Suzhou) Co. Ltd.

Recruiting

A Clinical Study of IBI130 for Subjects With Unresectable, Locally Advanced or Metastatic Solid Tumors

Solid Tumor

Australia
Innovent Biologics (Suzhou) Co. Ltd.

Not yet recruiting

A Phase Ib Study of Primary Efficacy and Safety of IBI321 Monotherapy or Combination Therapy in Patients With Advanced Solid Tumors

Advanced Solid Tumors

China
Shenzhen People's Hospital

Recruiting

Evaluate the Efficacy and Safety of IBI306 in Subjects With Homozygous Familial Hypercholesterolemia

Lipid Metabolism Disorders | Familial Hypercholesterolemia - Homozygous | Proprotein Convertase Subtilisin/Kexin 9

China
Innovent Biologics (Suzhou) Co. Ltd.

Completed

A Study of the Safety and Tolerability of IBI321 in Patients With Advanced Solid Tumors

Advanced Solid Tumors

China
Innovent Biologics (Suzhou) Co. Ltd.

Completed

A Study of IBI310 for the Treatment of Patients With Advanced Solid Tumors.

Advanced Solid Tumors

China
Innovent Biologics (Suzhou) Co. Ltd.

Not yet recruiting

Efficacy and Safety of IBI110 Single Agent and in Combination With Sintilimab in Patients With Relapsed or Refractory Diffuse Large B Cell Lymphoma (r/r DLBCL)

DLBCL

China
Innovent Biologics (Suzhou) Co. Ltd.

Recruiting

A Study of IBI363 in Subjects With Advanced Melanoma

Melanoma

China
Innovent Biologics (Suzhou) Co. Ltd.

Recruiting

A Study of IBI129 in Subjects With Unresectable, Locally Advanced or Metastatic Solid Tumors

Solid Tumor

Australia
Innovent Biologics (Suzhou) Co. Ltd.

Recruiting

Study of IBI323 in Patients With Advanced Malignancies

Advanced Malignancies

China
Innovent Biologics (Suzhou) Co. Ltd.

Active, not recruiting

Study of IBI333 in Subjects With Neovascular Age-related Macular Degeneration

Neovascular Age-related Macular Degeneration

China
Innovent Biologics (Suzhou) Co. Ltd.

Completed

Pharmacokinetics of IBI362 in Subjects With and Without Renal Impairment

Renal Impairment

China
Innovent Biologics (Suzhou) Co. Ltd.

Completed

A Dose Escalation Study of IBI324 in Subjects With Diabetic Macular Edema

Diabetic Macular Edema

China
Innovent Biologics (Suzhou) Co. Ltd.

Not yet recruiting

A Study of IBI363 in Subjects With Advanced Solid Malignancies

Solid Tumors

United States
Innovent Biologics (Suzhou) Co. Ltd.

Recruiting

A Multicentre,Study of IBI133 in Subjects With Unresectable, Locally Advanced or Metastatic Solid Tumours

Locally Advanced Unresectable or Metastatic Solid Tumors

Australia
Innovent Biologics (Suzhou) Co. Ltd.

Recruiting

A First-in-human Study of IBI343 in Subjects With Locally Advanced Unresectable or Metastatic Solid Tumors

Locally Advanced Unresectable or Metastatic Solid Tumors

Australia
Innovent Biologics (Suzhou) Co. Ltd.

Completed

Study to Evaluate the Safety, Tolerance, Pharmacokinetics and Preliminary Efficacy of IBI345

CLDN18.2 Positive Solid Tumors

China
Innovent Biologics (Suzhou) Co. Ltd.

Completed

A Study of Dose Escalation of IBI321 in Patients With Advanced Solid Tumors

Advanced Solid Tumors

China
Innovent Biologics (Suzhou) Co. Ltd.

Completed

IBI308 in Subjects With Advanced/Metastatic Solid Malignancies

Advanced/Metastatic Solid Malignancies

United States

3

Subscribe